Malignant migrating partial seizures of infancy controlled by stiripentol and clonazepam

Dana Merdariu1, Catherine Delanoë, Nora Mahfoufi

  • 1APHP, Hôpital Robert Debré, Service de Neurologie Pédiatrique, Paris, France.

Brain & Development
|April 24, 2012
PubMed

Insights

Malignant migrating partial seizures of infancy (MMPSI) is a severe epilepsy syndrome. A combination therapy of clonazepam, levetiracetam, and stiripentol achieved sustained seizure control in a reported case.

Area of Science:

  • Epilepsy research
  • Pediatric neurology
  • Pharmacology

Background:

  • Malignant migrating partial seizures of infancy (MMPSI) presents with early-onset, diverse seizure types and a poor prognosis.
  • Seizures in MMPSI are typically drug-resistant, with limited evidence on effective treatments.

Observation:

  • This report details a single case of MMPSI.
  • The patient experienced prolonged seizure control through a combination therapy.

Findings:

  • The treatment regimen included clonazepam, levetiracetam, and stiripentol.
  • This combination achieved sustained and complete seizure control, a rare outcome in MMPSI.

Implications:

  • This case suggests that a specific combination therapy may offer complete and sustained seizure control in MMPSI.
  • Further research into combination therapies is warranted for this challenging pediatric epilepsy syndrome.

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures ll: Types01:19

Seizures ll: Types

Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...